Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005227235
Tue, 28.11.2023
Biotest AG
PRESS RELEASE
Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation
Trimodulin is a globally unique, innovative human plasma protein preparation in advanced development for treatment of pneumonia
Trimodulin supports and modulates the dysregulated immu [ … ]
Thu, 02.11.2023
Biotest AG
PRESS RELEASE
Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023
Turnover grows by 38.7 % to Euro 500 million
Technology transfer and licensing agreement concluded with Grifols
Two new plasma centres opened
Dreieich, 2 November 2023: In the first nine months of the 2023 financial year, the Biotest Group recorded r [ … ]
Thu, 21.09.2023
Biotest AG
PRESS RELEASE
Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK
New approval enables future sales growth
Important therapeutic option for paediatric and adult patients with congenital and acquired immunodeficiencies as well as for immunomodulation
Manufactured in highly efficient Biotest Next Level produc [ … ]
Tue, 12.09.2023
Biotest AG
PRESS RELEASE
Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin
Trimodulin is a globally unique, innovative human plasma protein preparation in advanced development
Development in a therapeutic area of high unmet medical need
Significant reduction in mortality expected i [ … ]
Thu, 07.09.2023
Biotest AG
PRESS RELEASE
US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin Yimmugo
First marketing authorization application for a Biotest product from new "Biotest Next Level" production facility for the USA
Important milestone in the approval process of Yimmugo for the USA
Dreieich, 7 Sep [ … ]
Tue, 05.09.2023
Biotest AG
PRESS RELEASE
Biotest treats first shingles patient with Varitect® CP in VARIZOSTA study
High medical need in severe cases of herpes zoster (shingles) and resulting severe chronic nerve pain.
Observational study with 160 patients to generate data to optimise treatment strategy for herpes zoster
Proof of efficacy and safety of Var [ … ]
Mon, 04.09.2023
Biotest AG
PRESS RELEASE
Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years
Dr Jörg Schüttrumpf to remain Chief Scientific Officer (CSO) of Biotest AG for another 5 years
Appointment as Chief Scientific Innovation Officer of Grifols S.A.
Dreieich, 4 September 2023. The Supervisory Board of Biotest AG [ … ]
Thu, 10.08.2023
Biotest AG
PRESS RELEASE
Biotest increases EBIT to Euro 19.8 million in the first half of 2023
Turnover grows by 8.8 % to Euro 275 million
Technology transfer and licensing agreement concluded with Grifols
Two new plasma centres opened
Dreieich, 10 August 2023: In the first half of the 2023 financial year, the Biotest Group recorded revenues of € [ … ]
Thu, 27.07.2023
Biotest AG
PRESS RELEASE
Biotest increases EBIT to Euro 19.8 million
Sales revenue grows by 8.8 % to € 275 million
Technology transfer and licensing agreement signed with Grifols
Two new plasma centers opened
Dreieich, 27 July 2023. In the first half of the 2023 financial year, the Biotest Group recorded sales revenues of € 275.3 million. This corresp [ … ]
Thu, 27.07.2023
Biotest AG
PRESS RELEASE
Biotest increases EBIT to Euro 19.8 million
Sales revenue grows by 8.8 % to € 275 million
Technology transfer and licensing agreement signed with Grifols
Two new plasma centers opened
Dreieich, 27 July 2023. In the first half of the 2023 financial year, the Biotest Group recorded sales revenues of € 275.3 million. This corresp [ … ]